GENMAB AS SP.ADR/1/10DK 1 Cash Flow Reinvestment Rate
GENMAB AS SP.ADR/1/10DK 1 cash flow reinvestment rate. GENMAB AS SP.ADR/1/10DK 1 (GE91) has a Cash Flow Reinvestment Rate of 5.54x as of December 2025, reinvesting €1.67 Billion (capex €13.00 Million plus investments €1.66 Billion) from operating cash flow of €301.00 Million. Explore GE91 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of GENMAB AS SP.ADR/1/10DK 1 (2021–2025)
Cash flow reinvestment rate of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025. Historical reinvestment intensity for GENMAB AS SP.ADR/1/10DK 1 across 5 annual periods. Explore GE91 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
GENMAB AS SP.ADR/1/10DK 1 Cash Flow Reinvestment Rate by Year (2021–2025)
GENMAB AS SP.ADR/1/10DK 1 cash flow reinvestment rate by year from 2021 to 2025. Year-by-year capital reinvestment analysis for GENMAB AS SP.ADR/1/10DK 1. For the full cash flow conversion analysis, see cash flow conversion of GENMAB AS SP.ADR/1/10DK 1.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.42x | €1.68 Billion | €1.19 Billion | €55.00 Million | ▲ +274.0% |
| 2024 | 0.38x | €411.16 Million | €1.08 Billion | €42.41 Million | ▲ +118.3% |
| 2023 | 0.17x | €190.34 Million | €1.10 Billion | €55.83 Million | ▼ -75.4% |
| 2022 | 0.71x | €397.39 Million | €563.05 Million | €45.63 Million | ▲ +63.6% |
| 2021 | 0.43x | €146.30 Million | €339.18 Million | €38.36 Million | — |